GlassScriptPhysician profile
Joseph O Rahimian
NPI 1659344653
$16,134.33
in general payments reported to CMS, 2019-2025
35 companies · $5,053 in 2025
The $5,053 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $623 · 2021: $1,841 · 2022: $1,769 · 2023: $2,758 · 2024: $2,749 · 2025: $5,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,811 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,810.63 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,785.71 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $4,350.34 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Janssen Biotech, INC. | $1,626.37 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,334.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,176.03 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Shionogi INC | $393.85 | 2022-2025 | Fetroja |
| Melinta Therapeutics, LLC | $194.52 | 2019-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Theratechnologies INC. | $134.74 | 2020-2023 | Egrifta, Trogarzo |
| Allergan, INC. | $130.09 | 2019-2020 | |
| Hologic Sales and Service, LLC | $107.83 | 2024 | Aptima |
| Axsome Therapeutics, INC. | $76.02 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $73.74 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $63.85 | 2020-2022 | |
| Napo Pharmaceuticals INC | $60.59 | 2019-2025 | Mytesi |
| Lilly USA, LLC | $60.04 | 2024 | Zepbound, Mounjaro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $59.98 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.99 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $52.76 | 2025 | Vowst |
| Pfizer INC. | $47.68 | 2025 | |
| Paratek Pharmaceuticals, INC. | $44.24 | 2021-2025 | Nuzyra |
| Emd Serono, INC. | $44.19 | 2019-2022 | |
| Corium, LLC | $31.28 | 2025 | Azstarys |
| Cleerly, INC. | $30.41 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Philips North America LLC | $28.00 | 2024 | (Ck7) Extended Holter |
| Otsuka America Pharmaceutical, INC. | $27.90 | 2023 | Rexulti, Abilify Asimtufii |
| Daiichi Sankyo INC. | $27.17 | 2024 | Injectafer |
| Shield Therapeutics INC | $21.58 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.09 | 2019 | |
| Antares Pharma, INC. | $18.68 | 2025 | Xyosted |
| Seqirus USA INC | $14.50 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2025 | Trintellix |
| Phadia US INC. | $13.89 | 2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2023 | Xifaxan |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Rahimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.